Sagimet Biosciences Inc. Overview
Pro stress-test →Sagimet Biosciences is a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases resulting from dysfunctional metabolic pathways. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis.
Strategic Profile
Pro stress-test →In addition to MASH, the company is evaluating denifanstat in acne and in select forms of cancer, with denifanstat being tested in a Phase III clinical trial for moderate to severe acne vulgaris and a Phase III trial for recurrent glioblastoma multiforme in combination with bevacizumab. Sagimet has a global exclusive license with TAPI for innovative forms of resmetirom API to support a fixed-dose combination program combining resmetirom with denifanstat, with a Phase 3 study planned.
Competitive Landscape
Pro stress-test →Sagimet operates in the metabolic dysfunction-associated steatohepatitis (MASH) and acne treatment space. Competitors include Madrigal Pharmaceuticals and other FASN inhibitor developers. The company differentiates through its multi-indication platform (MASH, acne, oncology) and partnership strategies.
Industry Context
Sagimet Biosciences Inc. operates in Clinical-stage Biopharmaceuticals / Metabolic Disease Therapeutics.
Key facts
Founded: 2006 · Headquarters: San Mateo, California · Market cap: $167-252M